Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.8.0.1
Accrued Expenses
 9 Months Ended
Sep. 30, 2017
Payables and Accruals [Abstract]  
Accrued Expenses

7. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    September 30, 2017     December 31, 2016  
             
Accrued clinical operations and trials costs   $ 1,395,736     $ 1,647,490  
Accrued product development costs     885,063       713,426  
Accrued compensation     131,905       778,250  
Accrued other     145,898       117,289  
Total   $ 2,558,602     $ 3,256,455